Query

Filter the atlas

Across toxicity, chemistry, target, and ascertainment · 99 ADCs

99 of 99 ADCs

ADC	Target	Payload	DAR	OAE any ↓	OAE G3+	Keratopathy	Ascertainment	Approval
A166	ERBB2	Auristatin	2	100%	40.7%	84%	systematic	Approved (ex-US)
DP-303c	ERBB2	Auristatin	2	94.7%	21.3%	87.2%	systematic	Investigational
Depatuxizumab mafodotin	EGFR	Auristatin	4	94%	60%	94%	systematic	Discontinued
Belantamab mafodotin	TNFRSF17	Auristatin	4	92%	77%	86%	systematic	FDA-approved
AGS-16C3F	ENPP3	Auristatin	4	85%	21%	59%	systematic	Discontinued
Denintuzumab mafodotin (NHL)	CD19	Auristatin	4	84%	—	84%	systematic	Discontinued
Trastuzumab duocarmazine	ERBB2	DNA alkylator	2.8	78.1%	21.2%	38.2%	systematic	Discontinued
IMGC-936	ADAM9	Maytansinoid	2	77.8%	—	25%	systematic	Discontinued
CRB-701 (SYS6002)	NECTIN4	Auristatin	2	66%	5.4%	49.2%	partial-unspecified	Investigational
ZV0203	ERBB2	Auristatin	2	60%	26.7%	60%	symptom-driven	Investigational
Mirvetuximab soravtansine	FOLR1	Maytansinoid	3.4	59%	11%	36%	systematic	FDA-approved
Vorsetuzumab mafodotin	CD70	Auristatin	4	57%	23%	15%	symptom-driven	Discontinued
JBH-492	CCR7	Maytansinoid	3.8	56.3%	—	—	partial-unspecified	Discontinued
Denintuzumab mafodotin (ALL)	CD19	Auristatin	4	56%	—	56%	systematic	Discontinued
FS-1502	ERBB2	Auristatin	2	55.3%	2.7%	18%	symptom-driven	Investigational
Tisotumab vedotin	F3	Auristatin	4	55%	3.3%	17%	systematic	FDA-approved
MEDI2228	TNFRSF17	PBD dimer	2	53.7%	17.1%	0%	symptom-driven	Discontinued
Cantuzumab ravtansine	MUC1	Maytansinoid	3.5	50%	—	—	symptom-driven	Discontinued
Praluzatamab ravtansine	ALCAM	Maytansinoid	3.5	49%	11%	9%	partial-unspecified	Investigational
Iladatuzumab vedotin	CD79B	Auristatin	2	47%	8%	28%	symptom-driven	Investigational
MYTX-011	MET	Auristatin	2	47%	20%	41%	systematic	Investigational
ARX788	ERBB2	Auristatin	2	46.4%	4.3%	46.4%	partial-unspecified	Investigational
ARX-305	CD70	Auristatin	2	46.3%	0%	41.5%	unknown	Investigational
Zanidatamab zovodotin (ZW49)	ERBB2	Auristatin	2	45%	3%	45%	symptom-driven	Discontinued
XB-002 (Samatatug zovodotin)	F3	Auristatin	3.8	42%	0%	0%	partial-unspecified	Discontinued
Upifitamab rilsodotin	SLC34A2	Auristatin	—	41%	9%	3%	systematic	Discontinued
Aprutumab ixadotin	FGFR2	Auristatin	4.1	40%	5%	20%	systematic	Discontinued
Enfortumab vedotin	NECTIN4	Auristatin	3.8	40%	0.7%	—	systematic	FDA-approved
PF-06263507	TPBG	Auristatin	4	38.5%	3.8%	3.8%	symptom-driven	Discontinued
Datopotamab deruxtecan	TACSTD2	Topoisomerase I inhibitor	4	38%	3.4%	24%	systematic	FDA-approved
Tusamitamab ravtansine	CEACAM5	Maytansinoid	3.8	38%	12%	29.3%	symptom-driven	Discontinued
Anetumab ravtansine	MSLN	Maytansinoid	3.2	37%	2%	37%	partial-unspecified	Discontinued
SAR-566658	MUC1 (CA6 epitope carried on MUC1)	Maytansinoid	3.5	36%	7.9%	35%	systematic	Discontinued
AGS-16M8F	ENPP3	Auristatin	4	31%	3.8%	—	symptom-driven	Discontinued
TRPH-222	CD22	Maytansinoid	2	31%	6%	—	symptom-driven	Discontinued
AMG-224	TNFRSF17	Maytansinoid	—	30%	0%	0%	symptom-driven	Discontinued
Sirtratumab vedotin	SLITRK6	Auristatin	4	29%	2.2%	15.1%	systematic	Discontinued
MRG-004A	F3	Auristatin	3.8	27%	—	—	symptom-driven	Investigational
Coltuximab ravtansine	CD19	Maytansinoid	3.5	25%	0%	1.6%	symptom-driven	Investigational
Telisotuzumab vedotin	MET	Auristatin	3.1	25%	1.2%	11%	symptom-driven	FDA-approved
Samrotamab vedotin (ABBV-085)	LRRC15	Auristatin	2	24.4%	0%	—	symptom-driven	Discontinued
SYSA-1801	CLDN18	Auristatin	2	21.2%	—	—	partial-unspecified	Discontinued
Lifastuzumab vedotin	SLC34A2	Auristatin	3.5	20%	10%	—	symptom-driven	Discontinued
Vobramitamab duocarmazine	CD276	Duocarmycin	2.7	19.8%	—	—	partial-unspecified	Discontinued
LY3076226 (IMC-D11)	FGFR3	Maytansinoid	—	12%	0%	4%	systematic	Discontinued
Trastuzumab deruxtecan	ERBB2	Topoisomerase I inhibitor	8	11%	0.4%	—	symptom-driven	FDA-approved
AB-160	VEGFA	Taxane	—	10%	0%	—	symptom-driven	Investigational
BMS-986148	MSLN	Tubulysin	3	10%	1.7%	—	systematic	Discontinued
DLYE5953A (RG-7841)	LY6E	Auristatin	2	10%	0%	—	symptom-driven	Discontinued
JK-06	TPBG	Auristatin	2	10%	2%	8.8%	symptom-driven	Investigational
PF-06804103	ERBB2	Auristatin	4	9.5%	0%	9.7%	symptom-driven	Discontinued
Pinatuzumab vedotin	CD22	Auristatin	3.5	9.5%	0%	—	symptom-driven	Investigational
Farletuzumab ecteribulin	FOLR1	Microtubule (other)	4	9%	0%	—	symptom-driven	Investigational
Moxetumomab pasudotox	CD22	Other	—	9%	0%	—	symptom-driven	FDA-approved
AVID-100	EGFR	Maytansinoid	3.5	8%	0%	8%	systematic	Discontinued
PF-06647263	EFNA4	Calicheamicin	4.6	8%	0%	—	symptom-driven	Investigational
Serclutamab talirine (ABBV-321, EGFR, PBD/SGD-1882)	EGFR	PBD dimer	2	7%	0%	2%	symptom-driven	Discontinued
PF-06664178	TACSTD2	Auristatin	2	6.5%	0%	—	symptom-driven	Discontinued
Indatuximab ravtansine	SDC1	Maytansinoid	3.5	6.3%	—	3.1%	symptom-driven	Discontinued
BRY-812	SLC39A6	Auristatin	—	5.9%	—	—	symptom-driven	Investigational
MEN-1309 (OBT076)	LY75	Maytansinoid	3.7	5.9%	0%	—	symptom-driven	Investigational
Brentuximab vedotin	TNFRSF8	Auristatin	4	5%	0%	—	symptom-driven	FDA-approved
Disitamab vedotin	ERBB2	Auristatin	4	5%	0%	—	symptom-driven	Approved (ex-US)
PF-06650808	NOTCH3	Auristatin	4	5%	—	—	symptom-driven	Discontinued
Sacituzumab govitecan	TACSTD2	Topoisomerase I inhibitor	7.6	5%	0%	—	symptom-driven	FDA-approved
Trastuzumab emtansine	ERBB2	Maytansinoid	3.5	5%	0%	—	symptom-driven	FDA-approved
Lorvotuzumab mertansine	NCAM1	Maytansinoid	3.5	4.7%	0%	—	symptom-driven	Discontinued
SC-002 (rovalpituzumab, DLL3, PBD/SG3199)	DLL3	PBD dimer	2	2.9%	0%	—	symptom-driven	Discontinued
Patritumab deruxtecan	ERBB3	Topoisomerase I inhibitor	8	2.7%	0%	—	partial-unspecified	Investigational
Sacituzumab tirumotecan	TACSTD2	Topoisomerase I inhibitor	7.4	2.3%	0%	—	symptom-driven	Approved (ex-US)
Polatuzumab vedotin	CD79B	Auristatin	3.5	1.2%	0%	—	symptom-driven	FDA-approved
Camidanlumab tesirine	IL2RA	PBD dimer	2.3	0.9%	0%	—	symptom-driven	Discontinued
Rovalpituzumab tesirine	DLL3	PBD dimer	2	0.54%	1.4%	—	symptom-driven	Discontinued
ATG-022	CLDN18	Auristatin	4	0%	0%	0%	symptom-driven	Investigational
BAT-8006	FOLR1	Topoisomerase I inhibitor	7	0%	0%	0%	symptom-driven	Investigational
BAT-8008	TACSTD2	Topoisomerase I inhibitor	6	0%	0%	0%	symptom-driven	Investigational
BYON-3521	MET	Duocarmycin	1.8	0%	0%	—	systematic	Investigational
Cetuximab saratolacan	EGFR	Photosensitizer	3	0%	0%	—	symptom-driven	Approved (ex-US)
DMOT4039A	MSLN	Auristatin	3.5	0%	0%	—	symptom-driven	Investigational
EBC-129	CEACAM5; CEACAM6	Auristatin	3.5	0%	0%	0%	systematic	Investigational
Farletuzumab (naked Ab)	FOLR1	—	—	0%	0%	—	symptom-driven	Discontinued
FOR-46	CD46	Auristatin	3.3	0%	—	—	systematic	Investigational
Gemtuzumab ozogamicin	CD33	Calicheamicin	2.5	0%	0%	—	symptom-driven	FDA-approved
Glembatumumab vedotin	GPNMB	Auristatin	4.5	0%	0%	—	systematic	Discontinued
HDP-101	TNFRSF17	Amatoxin	2	0%	0%	0%	symptom-driven	Investigational
Indusatumab vedotin	GUCY2C	Auristatin	4.2	0%	0%	0%	systematic	Discontinued
Inotuzumab ozogamicin	CD22	Calicheamicin	6	0%	0%	0%	symptom-driven	FDA-approved
Loncastuximab tesirine	CD19	PBD dimer	2.3	0%	0%	—	symptom-driven	FDA-approved
M-9140	CEACAM5	Topoisomerase I inhibitor	8	0%	0%	0%	systematic	Investigational
OBI-999	FUT1/FUT2	Auristatin	4	0%	0%	0%	systematic	Discontinued
Rinatabart sesutecan	FOLR1	Topoisomerase I inhibitor	8	0%	—	0%	symptom-driven	Investigational
SC-011 / ABBV-011 (SC17, SEZ6, calicheamicin)	SEZ6	Calicheamicin	2	0%	0%	—	symptom-driven	Discontinued
STRO-001	CD74	Maytansinoid	2	0%	0%	0%	systematic	Discontinued
TORL-1-23	CLDN6	Auristatin	4	0%	0%	—	systematic	Investigational
Vadastuximab talirine	CD33	PBD dimer	2	0%	0%	—	systematic	Discontinued
XMT-1660 (Emiltatug ledadotin)	VTCN1	Auristatin	6	0%	0%	—	systematic	Investigational
XNW-27011	CLDN18	Topoisomerase I inhibitor	8	0%	0%	—	systematic	Investigational
Zilovertamab vedotin	ROR1	Auristatin	4	0%	0%	—	symptom-driven	Investigational
Trastuzumab rezetecan	ERBB2	Topoisomerase I inhibitor	5.7	—	3.3%	—	symptom-driven	Approved (ex-US)

Filters combine with AND across facets, OR within a facet. OAE rates carry ascertainment caveats — a symptom-driven trial reads lower than a systematic-exam trial. Natural-language query (ask a question in plain English) is the next phase on this same engine.